The Effect of Sleep on Tendon Cellular Adaptation (TSS)
The Effect of Sleep on Human Tendon Cellular Remodeling: a ex Vivo Pilot Study.
The goal of this observational study is to evaluate the effect of hormones which surge or diminish during different stages of sleep on collagen turnover in tendon cells. The main questions it aims to answer are:
- To evaluate the effect of serum taken from participants overnight on human tendon cell-derived collagen expression in a cell culture model.
- To evaluate whether tendon cell-derived collagen expression in a cell culture model is driven by changes in collagen synthesis or breakdown.
To evaluate the effect of sleep on tendon adaptation, blood will be taken from human participants overnight and used to treat a tendon cell culture model.
Visão geral do estudo
Status
Descrição detalhada
Recent clinical evidence has linked poor sleep with increased risk of musculoskeletal injury while evidence from basic biological models indicates that growth hormone and cortisol may regulate the turnover of collagen, a key structural protein in tendons. Growth hormone concentration in the blood surges during deep sleep (~1-2 hr after sleep onset), while cortisol concentration reaches a nadir at this same time. It remains unclear whether serum containing these hormones, collected during sleep itself, can modulate collagen turnover processes. Therefore, the purpose of this study is to evaluate the effect of hormones which surge or diminish during different stages of sleep on collagen turnover in tendon cells.
This study will use a within-subjects design to collect serum for ex vivo experiments. The total study duration will be ~8 days. Participants will first be screened to ensure compliance with our inclusion and exclusion criteria. Written informed consent will be obtained from participants that pass screening. Twelve participants will be recruited in total (6 male, 6 female). Participants will complete a 7 night sleep diary while wearing two wearable devices (an accelerometer to measure physical activity and basic sleep outcomes, worn on the waist; a Fitbit to estimate sleep stages and sleep onset). After the sleep diary, participants will arrive at the laboratory following an overnight fast for a resting venous blood collection. They will return to the laboratory to sleep overnight in the Nutrition and Metabolism Research Group's Bed Rest Facility. Approximately 95 minutes following sleep onset, participants will be briefly awoken for a venous blood draw (i.e., deep sleep sample), before returning to sleep. Four hours after the deep sleep sample, participants will be briefly woken up for a venous blood draw (i.e., REM sleep sample). Participants will then be allowed to finish their night of sleep in the facility.
Commercially available human tenocytes will be treated with serum from the different timepoints (morning, deep/early sleep, REM/late sleep) for 7 days. Following the 7 day treatment period, tenocytes will be collected and collagen I and III expression will be assessed by immunoblot while stable isotope tracers will be used to quantify collagen synthesis and breakdown.
The primary objective of the study is to evaluate the effect of the nocturnal biochemical milieu on human tenocyte-derived collagen expression in vitro. The secondary objectives of the study is to assess whether changes in collagen expression are due to altered collagen synthesis and/or breakdown.
Tipo de estudo
Inscrição (Estimado)
Contactos e Locais
Contato de estudo
- Nome: Paul L Babits, MSc
- Número de telefone: 647-609-4710
- E-mail: paul.babits@mail.utoronto.ca
Estude backup de contato
- Nome: Dan R Moore, PhD
- Número de telefone: 416-946-4088
- E-mail: dr.moore@utoronto.ca
Locais de estudo
-
-
Ontario
-
Kingston, Ontario, Canadá, K7L 3N6
- Recrutamento
- School of Kinesiology and Health Studies Building
-
Contato:
- Chris McGlory, PhD
- Número de telefone: 75410 613-533-6000
- E-mail: chris.mcglory@queensu.ca
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Método de amostragem
População do estudo
Resident of Kingston, Ontario
Descrição
Inclusion Criteria:
- healthy (determined using a medical screening questionnaire)
- between the ages of 18 and 35
- participants must be a non-smoker
- self-reported moderately active (>150 minutes of moderate-to-vigorous physical activity per week)
- self-reported weight stable (< 2 kg increase or decrease in weight over the previous 6 months)
- sleep ≥ 7 hours per night
- female participants must have a stable menstrual cycle (>3 months of 21-35 day cycle length).
Exclusion Criteria:
- have a BMI <18.5 or >29.9 kg/m2
- have a history of clinically diagnosed insomnia (>7 on the Insomnia Severity Index) or other sleep disorder (e.g., sleep apnea)
- use a hormonal contraceptive (oral or IUD)
- consume 7+ standard drinks per week (high risk range)
- use cannabis >1 time per week
- have any concurrent medical, orthopedic, or psychiatric condition that, in the opinion of the investigators, would compromise the ability to comply with the study requirements
- regularly use anti-inflammatory and/or analgesic medication, whether prescription or not; use any medications known to affect collagen metabolism (e.g., glucocorticoids, acetaminophen, non-steroidal anti-inflammatory medication, or prescription strength acne medication, ACE inhibitors, proton pump inhibitors, growth hormone, GLP-1 receptor agonists);
- participated in a study involving a phenylalanine stable-isotope tracer in the previous year
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Modelos de observação: COHORT
- Perspectivas de Tempo: PROSPECTIVE
Coortes e Intervenções
Grupo / Coorte |
|---|
|
Healthy, young males and females.
Healthy, recreationally active, young adults (18-35) regularly getting > 7 h of sleep per night are the target population. There is no intervention for this study. |
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Collagen Expression
Prazo: Ex vivo experiments and immunoblot analysis will conclude approximately 12 weeks following serum collection.
|
Tenocyte-derived collagen expression will be assessed following a 7 day treatment period using daytime, early/deep sleep, and late/REM sleep by immunoblot. |
Ex vivo experiments and immunoblot analysis will conclude approximately 12 weeks following serum collection.
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Collagen Synthesis
Prazo: Ex vivo experiments and immunoblot analysis will conclude approximately 12 weeks following serum collection.
|
On the last day of the 7 day serum incubation, cells will be treated with a stable-isotope tracer for 6hrs to measure incorporation of this tracer into tenocyte collagen and thus collagen synthesis. |
Ex vivo experiments and immunoblot analysis will conclude approximately 12 weeks following serum collection.
|
|
Collagen breakdown
Prazo: Ex vivo experiments and immunoblot analysis will conclude approximately 12 weeks following serum collection.
|
Cells will be treated with a stable isotope tracer during a 7 day serum incubation. Six hours prior to collection, tracer will be withdrawn and tracer release into the media will be measured to estimate collagen breakdown. |
Ex vivo experiments and immunoblot analysis will conclude approximately 12 weeks following serum collection.
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Chris McGlory, PhD, Queen's University
- Investigador principal: Dan R Moore, PhD, University of Toronto
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Outros números de identificação do estudo
- TSS
- TISS FKPE Seed Grant (Número de outro subsídio/financiamento: Tanenbaum Institute for Science in Sport)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
This study is a collaboration between the McGlory and Moore research groups. Therefore, sleep and activity data will be shared between groups. Serum collected from sleep trials at the McGlory lab will also be shared with the Moore lab where ex vivo experiments will be conducted. However, no identifying information collected by the McGlory lab will be shared with the Moore lab.
Prazo de Compartilhamento de IPD
IPD collected by the McGlory lab will be made available to collaborators at the Moore lab following completion of data collection (estimated October 2026) until the time of publication (estimated November 2027).
Critérios de acesso de compartilhamento IPD
Paul Babits and Dr. Daniel Moore will have access sleep, activity data as well as serum collected during overnight trials. Electronic data will be shared via secure servers. Serum will be shipped between sites following the completion of data collection.
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .